Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Assembly Biosciences (ASMB) Capital Expenditures (2016 - 2025)

Assembly Biosciences has reported Capital Expenditures over the past 11 years, most recently at $24000.0 for Q4 2025.

  • Quarterly results put Capital Expenditures at $24000.0 for Q4 2025, changed N/A from a year ago — trailing twelve months through Dec 2025 was $66000.0 (up 135.71% YoY), and the annual figure for FY2025 was $66000.0, up 135.71%.
  • Capital Expenditures for Q4 2025 was $24000.0 at Assembly Biosciences, down from $42000.0 in the prior quarter.
  • Over the last five years, Capital Expenditures for ASMB hit a ceiling of $3.1 million in Q1 2021 and a floor of $14000.0 in Q1 2024.
  • Median Capital Expenditures over the past 5 years was $45000.0 (2023), compared with a mean of $354700.0.
  • Biggest five-year swings in Capital Expenditures: soared 4635.38% in 2021 and later plummeted 70.83% in 2024.
  • Assembly Biosciences' Capital Expenditures stood at $18000.0 in 2021, then skyrocketed by 466.67% to $102000.0 in 2022, then tumbled by 30.39% to $71000.0 in 2023, then tumbled by 80.28% to $14000.0 in 2024, then surged by 71.43% to $24000.0 in 2025.
  • The last three reported values for Capital Expenditures were $24000.0 (Q4 2025), $42000.0 (Q3 2025), and $14000.0 (Q2 2024) per Business Quant data.